Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography

British Journal of Surgery

Volumn 86, Issue 4, 1999, Pages 550-556

  Lucas, J D ^b   O'Doherty, M J ^a   Cronin, B F ^a   Marsden, P K ^a   Lodge, M A ^a   McKeet, P H ^a   Smith, M A ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER GRADING; CHILD; CLINICAL ARTICLE; EVALUATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; WHOLE BODY SCINTISCANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SARCOMA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032964666     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1999.01090.x     Document Type: Article

References (30)

1. 1 Clasby R, Tilling K, Smith MA, Fletcher CDM. Variable management of soft tissue sarcoma: regional audit with implications for specialist care. Br J Surg 1997; 84: 1692-6.
2. 2 Goodlad JR, Fletcher CDM, Smith MA. Surgical resection of primary soft-tissue sarcoma. Incidence of residual tumour in 95 patients needing re-excision after local resection. J Bone Joint Surg [Br] 1996; 78-B: 658-61.
3. 3 Mankin HJ, Mankin CJ, Simon MA, Members of the Musculoskeletal Tumor Society. The hazards of the biopsy, revisited. J Bone Joint Surg [Am] 1996; 78-A: 656-63.
4. 4 Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg [Am] 1982; 64-A: 1121-7.
5. 5 Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 1987; 205: 349-59.
6. 6 Enzinger FM, Weiss SW, eds. Soft Tissue Tumors. 3rd ed. St Louis, Missouri: Mosby, 1995.
7. 7 Pass HI, Dwyer A, Makuch R, Roth JA. Detection of pulmonary metastases in patients with osteogenic and soft-tissue sarcomas: the superiority of CT scans compared with conventional linear tomograms using dynamic analysis. J Clin Oncol 1985; 3: 1261-5.
8. 8 Bitran JD, Bekerman C, Golomb HM, Simon MA. Scintigraphic evaluation of sarcomata in children and adults by Ga67 citrate. Cancer 1978; 42: 1760-5.
9. 67Ga scintigraphy in soft-tissue sarcoma and chondrosarcoma. Radiology 1977; 123: 131-4.
10. 10 Southee AE, Kaplan WD, Jochelson MS, Gonin R, Dwyer JP, Antinan KH et al. Gallium imaging in metastatic and recurrent soft-tissue sarcoma. J Nucl Med 1992; 33: 1594-9.
11. 11 Kirchner PT, Simon MA. The clinical value of bone and gallium scintigraphy for soft-tissue sarcomas of the extremities. J Bone Joint Surg [Am] 1984; 66-A: 319-27.
12. 12 Menendez LR, Fideler BR, Mirra J. Thallium-201 scanning for the evaluation of osteosarcoma and soft-tissue sarcoma. A study of the evaluation and predictability of the histological response to chemotherapy. J Bone Joint Surg [Am] 1993; 75-A: 526-31.
13. 13 Terui S, Terauchi T, Abe H, Fukuma H, Beppu Y, Chuman K et al. On clinical usefulness of Tl-201 scintigraphy for the management of malignant soft tissue tumors. Ann Nucl Med 1994; 8: 55-64.
14. 14 Garcia R, Kim EE, Wong FCL, Korkmaz M, Wong WH, Yang DJ et al. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996; 37: 1476-9.
15. 99Tc(V) dimercaptosuccinic acid, a new tumour-seeking agent. Nucl Med Commun 1988; 9: 105-16.
16. 16 Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost effectiveness of FDG PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996; 37: 1428-36.
17. 17 Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-8.
18. 18 Griffeth LK, Dehdashti F, McGuire AH, McGuire DJ, Perry DJ, Moerlein SM et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992; 182: 185-94.
19. 19 Kern KA, Brunetti A, Norton JA, Chang AE, Malawer M, Lack E et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29: 181-6.
20. 20 Nieweg OE, Pruitn J, van Ginkel RJ, Hoekstra HJ, Paans AMJ, Molenaar WM et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37: 257-61.
21. 21 Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32: 1508-12.
22. 18F]FDG. J Comput Assist Tomogr 1990; 14: 960-2.
23. 23 Eary JF, Conrad EU, Bruckner JD, Folpe A, Hunt KJ, Mankoff A et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998; 4: 1215-20.
24. 24 Lucas JD, O'Doherty MJ, Wong JCH, Bingham JB, McKee PH, Fletcher CDM et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft tissue sarcomas. J Bone Joint Surg [Br] 1998; 80-B: 441-7.
25. 25 Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel I et al. Soft-tissue sarcoma of adults; study of pathological prognostic variables and definition of a histological grading system. Int J Cancer 1984; 33: 37-44.
26. 26 Griffiths HJ, Galloway HR, Thompson RC Jr, Suh JS, Nelson TE, Everson L et al. The use of MRI in the diagnosis of benign and malignant bone and soft tissue tumours. Australas Radiol 1993; 37: 35-9.
27. 27 Hermann G, Abdelwahab IF, Miller TT, Klein MJ, Lewis MM. Tumour and tumour-like conditions of soft tissue: magnetic resonance imaging features differentiating benign from malignant masses. Br J Radiol 1992; 65: 14-20.
28. 28 Kalmar JA, Eick JJ, Merritt CR, Shuler SE, Miller KD, McFarland GB et al. A review of applications of MRI in soft tissue and bone tumors. Orthopaedics 1988; 11: 417-25.
29. 29 Bloem JL, van der Woude HJ, Geirnaerdt M, Hogendoorn PCW, Taminiau AHM, Hermans J. Does magnetic resonance imaging make a difference for patients with musculoskeletal sarcoma? Br J Radiol 1997; 70: 327-37.
30. 30 Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35: 1308-12.